About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

xFOREST Therapeutics and Axcelead DDP Launch Joint Research Initiative on RNA Structure-Targeted Small Molecule Drug Discovery

By: via Business Wire

xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research collaboration aimed at developing RNA structure-targeted small molecule therapeutics for multiple diseases.

xFOREST has developed a proprietary drug discovery platform, “FOREST Technologies,” which integrates a custom-designed RNA structure library and high-throughput screening technology. The platform specializes in identifying small molecule compounds that target RNA structures—regions previously considered “undruggable” by conventional drug discovery approaches. In addition to its internal R&D efforts, xFOREST actively collaborates with pharmaceutical companies, positioning itself as a practical and innovative partner in the RNA-targeted drug discovery space.

Axcelead DDP, a drug discovery solution provider with a strong foundation in pharmaceutical R&D, continues to expand and strengthen its capabilities through both in-house development and strategic partnerships. The company offers integrated drug discovery services to a wide range of drug discovery businesses. Axcelead DDP views RNA-targeted small molecule drug discovery as a next-generation modality for small molecule therapeutics and is investing to expand its technological foundation in this field.

In this joint research, xFOREST and Axcelead DDP will work together to strengthen the RNA structure-targeted small molecule drug discovery platform, aiming to improve research efficiency and increase the probability of generating candidate compounds, with the ultimate goal of advancing the development of innovative RNA-targeted small-molecule therapeutics. Under the agreement, xFOREST will retain exclusive rights to develop and commercialize any selected small molecule compounds, while Axcelead DDP will be entitled to milestone payments from xFOREST.

“We are thrilled to begin this new joint research initiative with Axcelead DDP,” said Shunichi Kashida, Ph.D., Representative Director, President and CEO of xFOREST. “By combining Axcelead DDP’s extensive expertise in small molecule drug discovery with our advanced RNA analysis technologies, we are confident that we can accelerate the development of innovative RNA-targeted therapeutics, including those directed at mRNA and pre-mRNA. Driven by this challenge, we remain committed to delivering new treatment options to patients as swiftly as possible.”

“We are delighted to embark on this joint research with xFOREST, a leading company in RNA structure-targeted small molecule drug discovery,” said Kengo Okada, Ph.D., Representative Director, President and CEO of Axcelead DDP. “We are confident that this collaboration will further enhance our technological capabilities in this field. By strengthening our RNA drug discovery platform, we aim to provide high-quality solutions to clients facing complex research challenges, and contribute to the creation of innovative medicines.”

About xFOREST

xFOREST Therapeutics is a drug discovery platform provider, founded in Kyoto, Japan in May 2020, specializing in small molecule drug discovery targeting RNA. Leveraging its proprietary "FOREST technologies," the company enables the identification of small molecules that selectively bind to RNA and exhibit biological activity. This innovative approach opens new avenues for addressing disease areas driven by RNA targets that have been difficult to approach using conventional methods. Building on this advanced technological foundation, xFOREST Therapeutics offers comprehensive support across various stages of early drug discovery—from RNA structure-based molecule screening to evaluation and optimization. As a pioneering partner in RNA-targeted drug discovery, xFOREST Therapeutics is committed to advancing the field and unlocking new therapeutic possibilities.

https://www.xforestx.com/

About Axcelead DDP

Axcelead DDP is Japan’s first drug discovery solutions provider, established in July 2017 after inheriting the drug discovery platform from Takeda Pharmaceutical Company Limited. We provide comprehensive drug discovery services through a fully integrated research platform that consolidates all essential functions and infrastructure—including a large-scale compound library, screening, chemistry, pharmacology/biology, DMPK and safety—under one roof. Furthermore, by combining our extensive experience and expertise with a proprietary AI platform, we can rapidly generate high-quality novel drug candidate compounds. This integrated setup enables us to deliver efficient and flexible one-stop solutions through a seamless framework, tailored to meet diverse needs in drug discovery from target identification to bridging into clinical development.

For more information, please visit https://axcelead-us.com/

Contacts

More News

View More
AIRO Group's Pullback: An Undervalued Growth Opportunity?
Via MarketBeat
Topics Supply Chain
Tickers AIRO
Caterpillar Stock Hits All-Time High—Is There More Room to Run?
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers CAT
Berkshire-Backed Lennar Slides After Weak Q3 Earnings
Via MarketBeat
Topics ETFs
Tickers BRK-A BRK-B LEN
Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?
Via MarketBeat
Tickers GS HSY PEP
Coming in Hot: Retail Data Drives Momentum in 3 E-Commerce Stocks
Via MarketBeat
Topics Economy
Tickers AMZN ETSY SHOP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.